Inflammation and Depression in People With HIV

Eligibility Criteria

• * HIV infected on continuous antiretroviral therapy (ART) with plasma HIV RNA \<200 copies/ml for at least 12 months (on at least two previous clinic visits and confirmed at screening)
• * Current cluster of differentiation 4 (CD4+) \> 350 cells/microliter for at least twelve months (on at least two previous clinic visits and confirmed at screening)
• * A primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) major depression, current, or Bipolar, depressed type as diagnosed by the SCID-V
• * Score of ≥10 on the 9-item Patient Health Questionnaire (PHQ-9)
• * Off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks prior to baseline visit
• * Significant anhedonia as reflected by a score ≥ 2 on item #1 of the PHQ-9
• * CRP≥2mg/L
• * Women of reproductive age will have a negative serum pregnancy test at study entry and both mend and women must agree to adequate contraception while
• * \< 18 years of age or \> 65 years of age
• * Pregnancy or breastfeeding
• * Significant hematological abnormalities at screening (ANC \< 1500, Hgb\<10, platelet\< 100,000)
• * History of progressive multifocal leukoencephalopathy
• * Untreated latent tuberculosis infection (which will be screened for prior to entry)
• * Having taken the following immunosuppressive medications within the past 6 months:
• 1. Oral corticosteroids
• 2. Biologic treatments such as etanercept, infliximab, certolizumab, adalimumab, golimumab, tocilizumab, abatacept, Ustekinumab, ixekizumab, secukinumab, or anakinra
• 3. Cyclophosphamide (or any other cytotoxic agent), belimumab, or anifrolumab (or another anti-interferon (IFN) therapy)
• 4. Rituximab, any other B cell depleting therapies, or intravenous immunoglobulin (IVIg)
• 5. any Janus kinase (JAK) inhibitor
• * History of deep venous thrombosis
• * Cardiovascular disease:
• 1. Coronary artery disease or history of myocardial infarction
• 2. Congestive heart failure with left ventricular ejection fraction ≤40% per American Heart Association guidelines
• 3. Stroke history
• * Hematologic malignancies including lymphoma and leukemia
• * Major surgery within 8 weeks prior to screening or will require major surgery during the study
• * Current or recent (\<4 weeks prior to randomization) clinically serious viral (including coronavirus disease 2019 (COVID-19)), bacterial, fungal, or parasitic infection or any other active or recent infection
• * Symptomatic herpes simplex at the time of randomization
• * Symptomatic herpes zoster infection within 12 weeks prior to randomization
• * History of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement)
• * Positive test for hepatitis B virus (HBV) defined as:
• 1. positive for hepatitis B surface antigen (HBsAg), or
• 2. positive for hepatitis B core antibody (HBcAb) and positive for hepatitis B virus deoxyribonucleic acid (HBV DNA)
• * Hepatitis C virus (HCV) infection (hepatitis C antibody-positive and HCV ribonucleic acid \[RNA\]-positive)
• * Cirrhosis of the liver from any cause
• * Any of the following specific abnormalities on screening laboratory tests:
• 1. alanine transaminase (ALT) or aspartate aminotransferase (AST) \>2 x upper limits of normal (ULN)
• 2. alkaline phosphatase (ALP) ≥2 x ULN
• 3. total bilirubin ≥1.5 x ULN (with the exception of patients on atazanavir, who must have total bilirubin \<2 x ULN)
• * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<40 mL/min/1.73 m\^2
• * History of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; substance abuse/dependence within 6 months of study entry, as determined by severe combined immunodeficiency (SCID)
• * A positive urine drug screen for illicit drugs at any time during the study excluding marijuana
• * An active suicidal plan as determined by a score \>3 on item #3 on the Hamilton Rating Scale for Depression (HAM-D)
• * An active eating disorder or antisocial personality disorder
• * History of dementia
• * Chronic use of non-steroidal anti-inflammatory agents (NSAIDS) (excluding 81mg of aspirin), glucocorticoid containing medications or minocycline within 2 weeks of baseline or at any time during the study
• * Any contraindication for MRI scanning
• * Failure of more than 2 antidepressant trials (at least 6 weeks at recommended dose) in the current episode or 5 antidepressant trials lifetime
• * BMI \>42 (to exclude severe obesity) or at the investigator's discretion based on the patient's ability to fit in the MRI scanner